目的 探討金芪降糖片聯(lián)合西格列汀治療2型糖尿病的臨床療效。方法 選取北京電力醫(yī)院于2021年7月—2023年6月收治糖尿病患者120例，隨機(jī)分為對照組和治療組，每組各60例。對照組口服磷酸西格列汀片，100 mg/次，1次/d。治療組在對照組基礎(chǔ)上口服金芪降糖片，1.68 g/次，3次/d。兩組患者均治療3個月。觀察兩組患者臨床療效，比較治療前后兩組患者3個月內(nèi)三點(diǎn)主要不良心血管事件（3p-MACE）發(fā)生率，糖化血紅蛋白（HbA1c）、空腹血糖（FBG）及餐后2 h血糖（2 h PBG）、內(nèi)皮素（ET-1）、一氧化氮（NO）、腫瘤壞死因子-α（TNF-α）、C反應(yīng)蛋白（CRP）和白細(xì)胞介素-6（IL-6）水平。結(jié)果 治療后，治療組患者總有效率為93.33%，對照組患者總有效率為78.33%，兩組比較差異有統(tǒng)計學(xué)意義（P＜0.05）。治療后，兩組FBG、2 h PBG、HbA1c、TNF-α、CRP、IL-6和ET1水平較治療前明顯降低，而NO水平較治療前明顯升高（P＜0.05），且治療后治療組血糖水平、微炎癥和血管內(nèi)皮功能均明顯好于對照組（P＜0.05）。結(jié)論 金芪降糖片聯(lián)合西格列汀能有效降低2型糖尿病患者血糖，改善微炎癥及保護(hù)血管內(nèi)皮。

Objective To explore the clinical efficacy of Jinqi Jiangtang Tablets combined with sitagliptin in treatment of type 2 diabetes. Methods Patients (120 cases) with type 2 diabetes in Beijing Electric Power Hospital from July 2021 to June 2023 were randomly divided into control and treatment group, and each group had 60 cases. Patients in the control group were po administered with Sitagliptin Phosphate Tablets, 100 mg/time, once daily. Patients in the treatment group were po administered with Jinqi Jiangtang Tablets on the basis of the control group, 1.68 g/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical evaluations were evaluated, and the 3p-MACE of 3 months, the levels of FBG, 2 h PBG, HbA1c, NF-α, CRP, IL-6, NO and ET1 in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was 93.33%, and which in the control group was 78.33%, there was a statistically significant difference between the two groups (P < 0.05). After treatment, the levels of FBG, 2 h PBG, HbA1c, TNF-α, CRP, IL-6 and ET1 in two groups were significantly lower than before treatment, while the level of NO was significantly higher than before treatment (P < 0.05). After treatment, the blood sugar level, micro-inflammation and vascular endothelial function in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Jinqi Jiangtang Tablets combined with sitagliptin can effectively reduce blood glucose, improve micro-inflammation and protect vascular endothelium in patients with type 2 diabetes.

R977